Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Varsha Gandhi, PhD, on Ibrutinib

The Interventional Pharmacoeconomic Toolbox Panel Discussion

May

Today In Oncology

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Varsha Gandhi, PhD, on Ibrutinib

The Interventional Pharmacoeconomic Toolbox Panel Discussion

CRISPR-Cas9-Edited TILs Targeting Intracellular Immune Checkpoint CISH in Metastatic Colorectal Cancer

Antimicrobial Resistance in Outpatients With Cancer

Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma

Five Major Advances in Radiotherapy for Anal and Rectal Cancer Presented at ESTRO 2025

Breast Cancer Genome-Wide Study Identifies Two New Risk Genes in Black South African women